featured-image

, /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: ), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced that its U.S.

subsidiary, Wincal Biopharm, Inc. ("WincalBio"), gained agreat attention at the world's largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation. WincalBio revealed that currently marketed therapeutic antibodies can be delivered within the eyes using their proprietary Ocular Penetration Carrier (OPC) screening platform, as shown by animal studies.



This innovation suggests that non-invasive eye drops could potentially replace traditional intravitreal injection methods for treating eye diseases. The OPC screening platform was developed to identify antibody-carrier complexes capable of delivering therapeutic agents into the back of the eye, such as the vitreous, retina, and choroid, without relying on needle injections. This allows patients to administer treatment conveniently at home using eye drops.

The key to this technology is finding a matching carrier to each antibody to facilitate drug delivery inside the eye. At ARVO 2024, WincalBio gave an oral presentation that their OPC screening platform enabled the delivery of the anti-VEGF treatments, Eylea (aflibercept) and Beovu (brolucizumab), as eye drops. In a laser-induced choroid neovascularization (CNV) mo.

Back to Health Page